Literature DB >> 18577912

Fibrin glue to reduce seroma after axillary lymphadenectomy for breast cancer.

R Ruggiero1, E Procaccini, S Gili, C Cremone, G Docimo, G Decimo, F Iovino, L Docimo, L Decimo, L Sparavigna, A Gubitosi, A Subitosi, D Parmeggiani, N Avenia.   

Abstract

UNLABELLED: Axillary lymphadenectomy remains an integral part of breast cancer treatment, yet seroma formation occurs in 15-85% of cases. Among the methods employed to reduce seroma magnitude and duration, fibrin glue has been proposed in numerous studies with controversial
RESULTS: Sixty patients underwent quadrantectomy or mastectomy with level I/II axillary lymphadenectomy; a suction drain was fitted in all patients. Fibrin glue spray was applied to the axillary fossa in 30 patients; the other 30 patients were treated conventionally. Suction drainage was removed between postoperative days III and IV. Seroma magnitude and duration were significantly reduced (P=0.004 and 0.02, respectively), and there were fewer evacuative punctures, in patients receiving fibrin glue compared with the conventional treatment group. The authors conclude that the use of fibrin glue does not always prevent seroma formation, but does reduce seroma magnitude, duration and necessary evacuative punctures.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18577912

Source DB:  PubMed          Journal:  Minerva Chir        ISSN: 0026-4733            Impact factor:   1.000


  3 in total

Review 1.  Fibrin sealant: past, present, and future: a brief review.

Authors:  William D Spotnitz
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

Review 2.  Fibrin-based biomaterials: modulation of macroscopic properties through rational design at the molecular level.

Authors:  Ashley C Brown; Thomas H Barker
Journal:  Acta Biomater       Date:  2013-09-19       Impact factor: 8.947

3.  Axillary lymphadenectomy for breast cancer in elderly patients and fibrin glue.

Authors:  Giovanni Docimo; Paolo Limongelli; Giovanni Conzo; Simona Gili; Alfonso Bosco; Antonia Rizzuto; Vincenzo Amoroso; Salvatore Marsico; Nicola Leone; Antonio Esposito; Chiara Vitiello; Landino Fei; Domenico Parmeggiani; Ludovico Docimo
Journal:  BMC Surg       Date:  2013-10-08       Impact factor: 2.102

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.